Kamada has already obtained orphan drug designation from both the FDA and the EMEA for aerosolized Alpha-1 Antitrypsin (AAT) for the treatment of congenital emphysema and cystic fibrosis.
David Tsur, CEO of Kamada, said: “Kamada is strategically progressing towards registration of its AAT formulations in the European and US markets.”